Skip to main content
Premium Trial:

Request an Annual Quote

Elixir Closes $19M Series B Financing Round

NEW YORK, Oct. 13 (GenomeWeb News) - Elixir Pharmaceuticals said that it has secured another $19 million in its Series B financing, bringing the total raised to $40.5 million.


Elixir said that the $19 million was contributed by undisclosed new investors.  In a previous round of Series B financing, MPM Capital, Oxford BioScience Partners, and Arch Venture Partners purchased $21.5 million in Elixir equity.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.